Login to Your Account



'BLOOM' off the Rose: LibiGel Failure Sends BioSante Falling

By Catherine Shaffer
BioWorld Today Contributing Writer

Friday, December 16, 2011
BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., reported disappointing results from its two pivotal Phase III trials of LibiGel (testosterone gel) for hypoactive sexual desire disorder in postmenopausal women.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription